Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe : multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021
Abstract
Introduction : In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods : Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results : Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions : VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
Citation
Kissling , E , Hooiveld , M , Martinez-Baz , I , Mazagatos , C , William , N , Vilcu , A M , Kooijman , M N , Ilic , M , Domegan , L , Machado , A , De Lusignan , S , Lazar , M , Meijer , A , Brytting , M , Casado , I , Larrauri , A , Murray , J L K , Behillil , S , De Gier , B , Mlinaric , I , O'Donnell , J , Rodrigues , A P , Tsang , R , Timnea , O , de Lange , M , Riess , M , Castilla , J , Pozo , F , Hamilton , M , Falchi , A , Knol , M J , Filipovic , S K , Dunford , L , Guiomar , R , Cogdale , J , Cherciu , C , Jansen , T , Enkirch , T , Basile , L , Connell , J , Gomez , V , Martin , V S , Bacci , S , Rose , A M C , Celentano , L P , Valenciano , M & I-MOVE-COVID-19 primary care study team 2022 , ' Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe : multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021 ' , Eurosurveillance , vol. 27 , no. 21 , A1 . https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104
Publication
Eurosurveillance
Status
Peer reviewed
ISSN
1025-496XType
Journal article
Description
This project received funding from the European Centre for Disease Prevention and Control (ECDC) under the contract ECD.11486. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673.Collections
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.